An Open, Phase I, Dose Escalation Study of the Monoclonal Antibody TB-403 Directed Against PlGF, Given as Multiple IV-doses to Patients With Solid Tumors.
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Solid Tumors
Both
Solid Tumors
Trial Information
An Open, Phase I, Dose Escalation Study of the Monoclonal Antibody TB-403 Directed Against PlGF, Given as Multiple IV-doses to Patients With Solid Tumors.
Inclusion Criteria:
- Confirmed malignity
- Measurable disease
- Performance status 1 or less (ECOG)
Exclusion Criteria:
- Acute illness or infection
- Concurrent second malignancy
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Safety and tolerability of an anti-PlGF antibody
Outcome Time Frame:
85 days
Safety Issue:
No
Principal Investigator
Ulrik Lassen, MD, PhD
Investigator Role:
Study Chair
Investigator Affiliation:
Rigshospitalet, Denmark
Authority:
Denmark: Danish Medicines Agency
Study ID:
07-TB-403-02
NCT ID:
NCT00702494
Start Date:
June 2008
Completion Date:
September 2009
Related Keywords:
- Solid Tumors
- placental growth factor
- monoclonal antibody
- Phase I
- solid tumors
- Patients with solid tumors
- Neoplasms
Name | Location |
|---|
